姜黄素3通过恢复肺癌细胞内wif1表达 诱导肺癌细胞凋亡机制研究-study on mechanism of curcumin 3 inducing apoptosis of lung cancer cells by recovering wif 1 expression in lung cancer cells.docxVIP

目录英文缩写一览表 1英文摘要 3中文摘要 8第一部分姜黄素、去甲氧基姜黄素、双去甲氧基姜黄素在小细胞肺癌中对 WIF-1 启动子的去甲基化作用12前言 12材料与方法 13结果 24讨论 27参考文献 29第二部分双去甲氧基姜黄素抑制肺癌细胞 Wnt 通路活性及诱导凋亡研究32前言 32材料与方法 32结果 50讨论 58参考文献 60第三部分双去甲基姜黄素诱导 WIF-1 基因去甲基化的机制研究63前言 63材料与方法 63结果 76讨论 81参考文献 83全文结论 85致谢 86附图与照片 87 文献综述姜黄素抗肿瘤机制研究进展 92 参考文献 100攻读博士学位期间发表的论文 108英文缩写一览表缩略语英文全名中文全名Bdmcbisdemethylcurcumin双去甲氧基姜黄素Dmcdemethylcurcumin去甲氧基姜黄素NSCLCNon-small-cell lung cancer非小细胞肺癌DNMT1DNA methyltransferase-1DNA 甲基转移酶 1WIF-1Wnt inhibitory factor-1Wnt 抑制因子-1EGFRepidermal growth factor receptor表皮生长因子受体WntWingless/int signaling pathwayWingless/int信号通路FBSfetal bovine serum胎牛血清SAGMSmall airway epithelial cell basal medium小气道上皮细胞培养基DAC5-Aza-2’-deoxycytidine5-氮-2-脱氧胞苷DMSOdimethyl sulfoxide二甲基亚砜MSPMethylation-specific PCR甲基化 PCRPVDFpolyvinylidene fluoride聚偏二氟乙烯TUNELdUTP nick end-labelingdUTP 未端标记TNF-αtumor necrosis factor-α肿瘤坏死因子 αTBSTris-buffered saline三羟甲基氨基甲烷缓冲液TBSTTris-buffered saline containing Tween-20三羟甲基氨基甲烷Tween-20 缓冲液mRNAmessage RNA信使 RNAEMSAElectrophoretic mobility shift assay凝胶迁移滞后实验RT-PCRreverse transcription and polymerase chainreaction逆转录多聚酶链反应dNTPdeoxynucleoside triphosphate脱氧核苷三磷酸ReverTraAce(M-MuLV)Moloney murine leukemin virus Reversetranscriptase鼠白血病病毒逆转录酶Radom(dT)15Radom -deoxythymidine 15随机聚脱氧胸苷酸 15DTTDithiothreitol二硫苏糖醇RnasinRnase inhibitorRNA 酶抑制剂RpmRevolutions per minute每分钟转速The hypomethylation agent bisdemethoxycurcumin acts on the WIF-1 promoter and inhibits the canonical Wnt pathway and induction of apoptosis in humannon-small-cell lung cancerAbstractBackground and ObjectiveLung cancer is the most common cause of cancer-related mortality worldwide. The overall five-year survival rate for the patients with lung cancer is still below 15% although thegreat progress in the early diagnosis and chemotherapy， radiotherapy， immune therapy. Inrecent years，small-molecule inhibitors，most of which are epidermal growth factor receptor (EGFR)-targeted drugs such as gefitinib or erlotinib， have improved the trea